Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

• Main Authors: Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Neupane, Prakash, Bratland, Ase, Fuereder, Thorsten, Hughes, Brett G. M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Hong, Ruey-Long, Mendoza, Rene Gonzalez, Jia, Liyi, Chirovsky, Diana, Norquist, Josephine, Jin, Fan, Burtness, Barbara
• Format: Article
• Published: Elsevier 2022
• Subjects: R Medicine (General); Medical technology
• Online Access: http://eprints.um.edu.my/42907/

Objectives: To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumabchemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the phase 3 KEYNOTE-048 trial (NCT02358031). Materials and Methods: HRQoL w...